Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts China Trials of Novel LAG-3 Immunotherapy

publication date: Dec 6, 2019

Suzhou Innovent has dosed the first patient in a China Phase I trial of its anti-lymphocyte activation gene 3 (LAG-3) candidate in patients with advanced malignancies. A novel immunotherapy, IBI110 will be studied as a monotherapy and in combination with Tyvyt®, Innovent's approved anti-PD-1 antibody drug. IBI110 is designed to bind to LAG-3 on the surface of T cells and disturb the interaction between LAG-3 and MHCII, relieving the inhibiting effect of LAG-3 on T cell activation. Its mechanism is expected to be synergistic with PD-1/PD-L1 drugs. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.